BillionToOne, Inc. Class A Common Stock

BLLN

BillionToOne leverages groundbreaking molecular diagnostics technology, targeting massive prenatal and oncology testing markets with rapid revenue growth. Revenues more than doubled to $152 million in 2024, with growth continuing at such percentages while operating profits are reported here. Valuation stands at 15 times annualised sales, justified by accelerating growth and improving margins, but revenue concentration and competition pose risks.

REDWOOD CITY, Calif. , Nov. 6, 2025 /PRNewswire/ -- Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, a leading law firm in technology and life sciences transactions, represented long-time client BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company on a mission to make powerful and accessible genetic tests available to all, in its upsized initial public offering of 4.6 million shares of Class A common stock at a price to the public of $60 per share, generating approximately $273.1 million in aggregate gross proceeds.

Shares of BillionToOne rose 66.67% in their Nasdaq debut on Thursday, valuing the molecular diagnostics firm at $4.4 billion.

Molecular diagnostics firm BillionToOne raised $273.1 million in its U.S. initial public offering on Wednesday, pricing its shares above its marketed range.

MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the pricing of its upsized initial public offering of 4,551,100 shares of its Class A common stock, at a public offering price of $60.00 per share. In addition, BillionToOne has granted the underwriters a 30-day option to purchase up to an additional 682,665 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025, under the ticker symbol “BLLN.” The gross proceeds from the offering are expected to be approximately $273.1 million, without giving effect to the underwriters' option to purchase additional shares and before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on November 7, 2025, subject to the satisfaction of customary closing conditions.

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has launched the roadshow for its proposed initial public offering of 3,846,000 shares of its Class A common stock. In addition, BillionToOne intends to grant the underwriters a 30-day option to purchase up to an additional 576,900 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is currently expected to be between $49.00 and $55.00 per share. BillionToOne has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “BLLN.”

Molecular diagnostics firm BillionToOne said on Friday it was aiming at a valuation of up to $2.42 billion in its U.S. initial public offering.

BillionToOne, Inc. is rapidly growing in the prenatal and oncology diagnostics sectors, nearing operating breakeven, and has filed for a $100 million IPO. BLLN's revenue is driven mainly by its UNITY prenatal testing, with plans to expand into oncology diagnostics - a highly competitive market. Financials show sharply rising revenue, improved margins, lower operating losses, and a recent swing to positive operating cash flow.

Six IPOs debuted this week, while two SPACs listed. Thirteen IPOs and five SPACs also submitted initial filings. No traditional IPOs are currently scheduled for the week ahead as the government shutdown continues to mostly pause new issuance.

BillionToOne filed for an initial public offering in the United States on Tuesday.